Emerging Applications of Hypomethylating Agents in the Treatment of Glioblastoma (Review)

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2024 Jul 15

PMID 39006906

Authors

Thenzing J Silva-Hurtado

Julio F Inocencio

Raymund L Yong

Affiliations

Soon will be listed here.

Abstract

DNA hypomethylating agents (HMAs) such as decitabine and 5-azacytidine have established roles in the treatment paradigms for myelodysplastic syndrome and acute myelogenous leukemia, where they are considered to exert their anticancer effects by restoring the expression of tumor suppressor genes. Due to their relatively favorable adverse effect profile and known ability to pass through the blood-brain barrier, applications in the treatment of glioblastoma (GBM) and other central nervous system malignancies are under active investigation. The present review examines the types of HMAs currently available, their known and less-understood antineoplastic mechanisms, and the evidence to date of their preclinical and clinical efficacy in glioblastoma and other solid malignancies. The present review discusses the potential synergies HMAs may have with established and emerging GBM treatments, including temozolomide, immune checkpoint inhibitors and cancer vaccines. Recent successes and setbacks in clinical trials for newly diagnosed and recurrent GBM are summarized in order to highlight opportunities for HMAs to improve therapeutic responses. Challenges for future clinical trials are also assessed.

References

Keskin D, Anandappa A, Sun J, Tirosh I, Mathewson N, Li S . Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2018; 565(7738):234-239. PMC: 6546179. DOI: 10.1038/s41586-018-0792-9. View

Federici L, Capelle L, Annereau M, Bielle F, Willekens C, Dehais C . 5-Azacitidine in patients with IDH1/2-mutant recurrent glioma. Neuro Oncol. 2020; 22(8):1226-1228. PMC: 7594550. DOI: 10.1093/neuonc/noaa074. View

Alnahhas I, Alsawas M, Rayi A, Palmer J, Raval R, Ong S . Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. Neurooncol Adv. 2020; 2(1):vdaa082. PMC: 7596890. DOI: 10.1093/noajnl/vdaa082. View

Chabot G, Rivard G, Momparler R . Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. Cancer Res. 1983; 43(2):592-7. View

Rideout 3rd W, Coetzee G, Olumi A, Jones P . 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science. 1990; 249(4974):1288-90. DOI: 10.1126/science.1697983. View

Glover A, Chun H, Davies B, Hoth D . Azacitidine: 10 years later. Cancer Treat Rep. 1987; 71(7-8):737-46. View

Tabu K, Sasai K, Kimura T, Wang L, Aoyanagi E, Kohsaka S . Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res. 2008; 18(10):1037-46. DOI: 10.1038/cr.2008.270. View

Huang K, Ramnarayanan K, Zhu F, Srivastava S, Xu C, Tan A . Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer. Cancer Cell. 2018; 33(1):137-150.e5. DOI: 10.1016/j.ccell.2017.11.018. View

Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S . The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009; 23(6):1019-28. DOI: 10.1038/leu.2008.397. View

10.

Pappalardi M, Keenan K, Cockerill M, Kellner W, Stowell A, Sherk C . Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer. 2021; 2(10):1002-1017. PMC: 8594913. View

11.

Claus R, Hackanson B, Poetsch A, Zucknick M, Sonnet M, Blagitko-Dorfs N . Quantitative analyses of DAPK1 methylation in AML and MDS. Int J Cancer. 2011; 131(2):E138-42. PMC: 3463871. DOI: 10.1002/ijc.26429. View

12.

Ostrom Q, Price M, Neff C, Cioffi G, Waite K, Kruchko C . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020. Neuro Oncol. 2023; 25(12 Suppl 2):iv1-iv99. PMC: 10550277. DOI: 10.1093/neuonc/noad149. View

13.

Handy D, Castro R, Loscalzo J . Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation. 2011; 123(19):2145-56. PMC: 3107542. DOI: 10.1161/CIRCULATIONAHA.110.956839. View

14.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

15.

Ghoneim H, Fan Y, Moustaki A, Abdelsamed H, Dash P, Dogra P . De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell. 2017; 170(1):142-157.e19. PMC: 5568784. DOI: 10.1016/j.cell.2017.06.007. View

16.

Zhong J, Yang X, Chen J, He K, Gao X, Wu X . Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands. Nat Commun. 2022; 13(1):4795. PMC: 9378736. DOI: 10.1038/s41467-022-32311-2. View

17.

Palucka K, Banchereau J . Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12(4):265-77. PMC: 3433802. DOI: 10.1038/nrc3258. View

18.

Skiriute D, Vaitkiene P, Asmoniene V, Steponaitis G, Deltuva V, Tamasauskas A . Promoter methylation of AREG, HOXA11, hMLH1, NDRG2, NPTX2 and Tes genes in glioblastoma. J Neurooncol. 2013; 113(3):441-9. DOI: 10.1007/s11060-013-1133-3. View

19.

Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim W . IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro Oncol. 2016; 18(10):1402-12. PMC: 5035522. DOI: 10.1093/neuonc/now061. View

20.

Jabbour E, Issa J, Garcia-Manero G, Kantarjian H . Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008; 112(11):2341-51. PMC: 4784235. DOI: 10.1002/cncr.23463. View